CAR-T Therapy Promises Long-Lasting Lupus Remission
Key Questions
What results has CAR-T therapy shown in treating refractory lupus?
CAR-T therapy achieved over 2 years of remission without medications in the first refractory SLE patient treated in Erlangen in 2021. It demonstrated efficacy in a 15-patient series across autoimmune diseases, allowing treatment without immunosuppressants and spotlighting potential for immune reset in tough cases.
How does CAR-T therapy work for autoimmune diseases like lupus?
CAR-T therapy, originally developed for cancer, reprograms immune cells to target disease-driving mechanisms in autoimmune conditions. In lupus, it enters a precision immunotherapy era by addressing systemic lupus erythematosus through immune reset, as seen in early patient series.
What limitations have been observed with CAR-T therapy for lupus?
While promising with long-lasting remissions, plasma cell relapse has been noted in some cases. The treatment remains in development amid pipeline advances for autoimmune diseases.
CAR-T achieves >2yr remission off meds in first refractory SLE patient (Erlangen 2021) and 15-pt series across autoimmune diseases without immunosuppressants. Spotlights potential immune reset for tough cases amid pipeline advances, though plasma cell relapse noted.